Nuclear medicine harnesses radioisotopes for the diagnosis and treatment of disease. While the isotopes ^99mTc and ¹¹¹In have enabled the clinical diagnosis of millions of patients over the past 3 decades, more recent clinical translation of numerous ⁶⁸Ga/¹⁷⁷Lu-based radiopharmaceuticals for diagnostic imaging and therapy underscores the clinical utility of metal-based radiopharmaceuticals in mainstream cancer treatment. In addition to such established radionuclides, advancements in radioisotope production have enabled the production of radionuclides with a broad range of half-lives and emission properties of interest for nuclear medicine. Chemical means to form kinetically inert, in vivo-compatible species that can be modified with disease-targeting vectors is imperative. This presents a challenge for radiosiotopes of elements where the aqueous chemistry is still underdeveloped and poorly understood. Here, we discuss our efforts to date in exploring the aqueous, radioactive coordination chemistry of highly Lewis acidic metal ions and how our discoveries apply to the diagnosis and treatment of cancer in preclinical models of disease. The scope of this Account includes approaches to aqueous coordination of to-date understudied highly Lewis acidic metal ions with radioisotopes of emerging interest and the modulation of well-understood coordination environments of radio-coordination complexes to induce metal-catalyzed reactivity for separation and pro-drug applications.

中文翻译：

---

探索高路易斯酸性金属与核医学新兴同位素的水配位化学

核医学利用放射性同位素来诊断和治疗疾病。虽然同位素^99m Tc 和¹¹¹ In 在过去 30 年中已经使数百万患者能够进行临床诊断，但最近用于诊断成像和治疗的众多⁶⁸ Ga/ ¹⁷⁷ Lu 放射性药物的临床转化强调了金属基放射性药物的临床实用性主流癌症治疗中的放射性药物。除了这些已确定的放射性核素之外，放射性同位素生产的进步使得能够生产具有广泛的半衰期和核医学感兴趣的发射特性的放射性核素。化学方法必须形成动力学惰性、体内相容的物种，并且可以用疾病靶向载体进行修饰。这对元素的放射性同位素提出了挑战，因为水化学仍然不发达且了解甚少。在这里，我们讨论了迄今为止我们在探索高路易斯酸性金属离子的水性放射性配位化学方面所做的努力，以及我们的发现如何应用于临床前疾病模型中癌症的诊断和治疗。本帐户的范围包括迄今为止正在研究的高路易斯酸性金属离子与新兴感兴趣的放射性同位素的水配位方法，以及调制众所周知的放射性配位配合物的配位环境，以诱导金属催化反应性以进行分离和促进药物应用。